Successful DRP™ prediction of patients treated with 2X-121, the PARP inhibitor recently licensed from Eisai
Hoersholm, Denmark, August 1st, 2017 – Oncology Venture AB (OV:ST) announces that work on validating the Drug Response Predictor (DRP) for pipeline asset 2X-121 has been completed and that the developed DRP™ has been able to successfully identify responders and non-responders to treatment in 13 patients.“Having worked with a number of the leading PARP inhibitors where clinical benefit is seen in all patients with high-grade serous ovarian cancer though highest benefit is seen in BRCA mutated population. The clinical benefit of available HRD* tests is questionable as these tests are unable